Science

SMSbiotech has been developing cutting edge adult stem cell technology that aims at Providing safe, affordable and ethically grounded regenerative medicine. We developed a patented technology (US Patent No. 10,041,037) that can bio-manufacture human ECM, derived from unique cells, the Small Mobile Stem (SMS) cells. Further development established large, industrial-scale production capability.

Our technology will provide patients initially with access to high-quality, immuno-compatible, and affordable human (allogenic or autologous) ECMs. We have established proprietary techniques for the isolation and indefinite growth of native adult SMS cells. Consistent with their true stem cell characteristics, these cells have not been transformed or manipulated and are prime candidates for the future use in cell therapy and tissue engineering. This robust technology will enable the high-volume and reproducible production of human medical grade ECM, a crucial component of in vivo tissue regeneration and in vitro tissue reconstruction. Our technology will help facilitate the development of cost-effective methods for (1) skin regeneration, (2) vascular repair, and (3) scaffold and tissue engineering. All of these processes are essential for the rapid, safe, and effective healing of wounds to any organ.

Why SMS Cells Are Superior To Mesenchymal Stem Cells


∙ In contrast to embryonic and genetically engineered cells, Small Mobile Stem (SMS) cells are adult stem cells from adult human tissues and because of that they are considered largely safe.

∙ Adult stem cells, mainly Mesenchymal stem cells, have been gaining a lot of momentum in cell therapy. SMS cells however post significant and crucial advantages over Mesenchymal stem cells.

∙ Unlike adult Mesenchymal Stem Cells, SMS cells are isolated from regular blood and when injected into the bloodstream they are in their “natural habitat” unlike the Mesenchymal cells. SMS cells have very few to no histocompatibility proteins, meaning they are unlikely to induce a significant immune-reaction.

∙ Unlike Mesenchymal stem cells that target mainly the immune cells, SMS cells target several different cells that are significant to tissue regeneration.

∙ SMS cells activate mesenchymal stem cell proliferation and may induce the beneficial regenerative effects of endogenous MSC.

∙ SMS cells are sturdier, more robust, and easier to handle. SMS cells are much smaller and, unlike the Mesenchymal cells, will unlikely clog capillaries and get stuck in the lungs.

∙ SMS cells have the ability to proliferate extensively without the loss of functional potency, such as differentiation into other cells or production of regenerative factors, unlike Mesenchymal stem cells.